These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29420118)

  • 1. Optimal dose selection accounting for patient subpopulations in a randomized Phase II trial to maximize the success probability of a subsequent Phase III trial.
    Takahashi F; Morita S
    J Biopharm Stat; 2018; 28(5):870-883. PubMed ID: 29420118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of predictive probabilities in phase II and phase III clinical trials.
    Johns D; Andersen JS
    J Biopharm Stat; 1999 Mar; 9(1):67-79. PubMed ID: 10091910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing a series of decision-theoretic phase II trials in a small population.
    Hee SW; Stallard N
    Stat Med; 2012 Dec; 31(30):4337-51. PubMed ID: 22927289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Closeout of four phase II Vanguard trials and patient rollover into a large international phase III HIV clinical endpoint trial.
    Tavel JA; Fosdick L;
    Control Clin Trials; 2001 Feb; 22(1):42-8. PubMed ID: 11165422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decision making from Phase II to Phase III and the probability of success: reassured by "assurance"?
    Carroll KJ
    J Biopharm Stat; 2013; 23(5):1188-200. PubMed ID: 23957523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New designs for the selection of treatments to be tested in randomized clinical trials.
    Simon R; Thall PF; Ellenberg SS
    Stat Med; 1994 Mar 15-Apr 15; 13(5-7):417-29. PubMed ID: 8023026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bayesian dose finding design for dual endpoint phase I trials.
    Loke YC; Tan SB; Cai Y; Machin D
    Stat Med; 2006 Jan; 25(1):3-22. PubMed ID: 16013039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seamless Phase II/III combination study through response adaptive randomization.
    Wang L; Cui L
    J Biopharm Stat; 2007; 17(6):1177-87. PubMed ID: 18027224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose selection in seamless phase II/III clinical trials based on efficacy and safety.
    Kimani PK; Stallard N; Hutton JL
    Stat Med; 2009 Mar; 28(6):917-36. PubMed ID: 19152231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation.
    Morita S; Yamamoto H; Sugitani Y
    Stat Med; 2014 Oct; 33(23):4008-16. PubMed ID: 24820639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation.
    Nixon RM; O'Hagan A; Oakley J; Madan J; Stevens JW; Bansback N; Brennan A
    Pharm Stat; 2009; 8(4):371-89. PubMed ID: 19340851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An improved method of evaluating drug effect in a multiple dose clinical trial.
    Shen L
    Stat Med; 2001 Jul; 20(13):1913-29. PubMed ID: 11427949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
    Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
    Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An adaptive, phase II, dose-finding clinical trial design to evaluate L-carnitine in the treatment of septic shock based on efficacy and predictive probability of subsequent phase III success.
    Lewis RJ; Viele K; Broglio K; Berry SM; Jones AE
    Crit Care Med; 2013 Jul; 41(7):1674-8. PubMed ID: 23514753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].
    Arazo Garcés P; Omiste Sanvicente T
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():23-31. PubMed ID: 19195456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal decision-making in oncology development programs based on probability of success for phase III utilizing phase II/III data on response and overall survival.
    Götte H; Xiong J; Kirchner M; Demirtas H; Kieser M
    Pharm Stat; 2020 Nov; 19(6):861-881. PubMed ID: 32662598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing the data combination rule for seamless phase II/III clinical trials.
    Hampson LV; Jennison C
    Stat Med; 2015 Jan; 34(1):39-58. PubMed ID: 25315892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
    Taylor DJ; Grobler A; Abdool Karim SS
    Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The phase II/III transition. Toward the proof of efficacy in cancer clinical trials.
    Fazzari M; Heller G; Scher HI
    Control Clin Trials; 2000 Aug; 21(4):360-8. PubMed ID: 10913810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.